The multidisciplinary epilepsy surgical conference review frequently alters SOZ interpretation and surgical plans for drug-resistant epilepsy.

A 4-channel wearable seizure detection algorithm performance approaches the level of expert epileptologists for the detection of electrographic seizures.

Midazolam for refractory status epilepticus reduces 30-day mortality and complications versus propofol, though long-term outcomes are similar.

The Neurology Advisor Team spoke with Tracy Bedrosian, PhD at AES 2025 in Atlanta, Georgia. Neurology Advisor: “Can you describe your work in the epilepsy space?” ...

Cancer related cognitive impairment in patients can stem from the cancer itself as well as the therapies used to treat it.

The Food and Drug Administration has granted Breakthrough Therapy designation to zilganersen for the treatment of Alexander disease.

Tai chi is an effective alternative approach for the long-term management of chronic insomnia in middle-aged and older adults.

The FDA has approved Avance® (acellular nerve allograft-arwx) for the treatment of sensory nerve discontinuity.

The FDA is facing even more leadership changes as drug regulator Dr Richard Pazdur prepares to retire at the end of the month.

Immediate neuro-rehabilitative treatment following moderate or severe TBI is associated with reduced risk of Alzheimer disease.

Impaired kidney function is associated with increased circulating levels of most Alzheimer disease blood biomarkers.

The Neurology Advisor team will deliver comprehensive reports from AES 2025, held from December 5 to 9, in Atlanta, Georgia.